Hubbry Logo
DysenteryDysenteryMain
Open search
Dysentery
Community hub
Dysentery
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Dysentery
Dysentery
Dysentery
View on Wikipedia
from Wikipedia

Dysentery
Other namesBloody diarrhea
A depiction of a soldier with dysentery in the 'F' & 'H' Force Hospital, Canchanburi, Siam. Artist: Charles Thrale, 1943
SpecialtyInfectious disease
SymptomsBloody diarrhea, abdominal pain, fever[1][2]
ComplicationsDehydration[3]
DurationLess than a week[4]
CausesUsually Shigella or Entamoeba histolytica[1]
Risk factorsContamination of food and water with feces due to poor sanitation[5]
Diagnostic methodBased on symptoms, Stool test
PreventionHand washing, food safety[4]
TreatmentDrinking sufficient fluids, antibiotics (severe cases)[4]
FrequencyOccurs often in many parts of the world[6]
Deaths1.1 million a year[6]

Dysentery (UK: /ˈdɪsəntəri/ DISS-ən-tər-ee,[7] US: /ˈdɪsəntɛri/ DISS-ən-terr-ee),[8] historically known as the bloody flux,[9] is a type of gastroenteritis that results in bloody diarrhea.[1][10] Other symptoms may include fever, abdominal pain, and a feeling of incomplete defecation.[2][5][11] Complications may include dehydration.[3]

The cause of dysentery is usually the bacteria from genus Shigella, in which case it is known as shigellosis, or the amoeba Entamoeba histolytica; then it is called amoebiasis.[1] Other causes may include certain chemicals, other bacteria, other protozoa, or parasitic worms.[2] It may spread between people.[4] Risk factors include contamination of food and water with feces due to poor sanitation.[5] The underlying mechanism involves inflammation of the intestine, especially of the colon.[2]

Efforts to prevent dysentery include hand washing and food safety measures while traveling in countries of high risk.[4] While the condition generally resolves on its own within a week, drinking sufficient fluids such as oral rehydration solution is important.[4] Antibiotics such as azithromycin may be used to treat cases associated with travelling in the developing world.[11] While medications used to decrease diarrhea such as loperamide are not recommended on their own, they may be used together with antibiotics.[11][4]

Shigella results in about 165 million cases of diarrhea and 1.1 million deaths a year with nearly all cases in the developing world.[6] In areas with poor sanitation nearly half of cases of diarrhea are due to Entamoeba histolytica.[5] Entamoeba histolytica affects millions of people and results in more than 55,000 deaths a year.[12] It commonly occurs in less developed areas of Central and South America, Africa, and Asia.[12] Dysentery has been described at least since the time of Hippocrates.[13]

Signs and symptoms

[edit]

The most common form of dysentery is bacillary dysentery, which is typically a mild sickness, causing symptoms normally consisting of mild abdominal pains and frequent passage of loose stools or diarrhea. Symptoms normally present themselves after 1–3 days, and are usually no longer present after a week. The frequency of urges to defecate, the large volume of liquid feces ejected, and the presence of blood, mucus, or pus depends on the pathogen causing the disease. Temporary lactose intolerance can occur, as well. In some occasions, severe abdominal cramps, fever, shock, and delirium can all be symptoms.[2][14][15][16]

In extreme cases, people may pass more than one liter of fluid per hour. More often, individuals will complain of diarrhea with blood, accompanied by extreme abdominal pain, rectal pain and a low-grade fever. Rapid weight loss and muscle aches sometimes also accompany dysentery, while nausea and vomiting are rare.

On rare occasions, the amoebic parasite will invade the body through the bloodstream and spread beyond the intestines. In such cases, it may more seriously infect other organs such as the brain, lungs, and most commonly the liver.[17]

Cause

[edit]
Cross-section of diseased intestines. Colored lithograph c. 1843

Dysentery results from bacterial or parasitic infections. Viruses do not generally cause the disease.[10] These pathogens typically reach the large intestine after entering orally, through ingestion of contaminated food or water, oral contact with contaminated objects or hands, and so on. Each specific pathogen has its own mechanism or pathogenesis, but in general, the result is damage to the intestinal linings, leading to the inflammatory immune responses. This can cause elevated physical temperature, painful spasms of the intestinal muscles (cramping), swelling due to fluid leaking from capillaries of the intestine (edema) and further tissue damage by the body's immune cells and the chemicals, called cytokines, which are released to fight the infection. The result can be impaired nutrient absorption, excessive water and mineral loss through the stools due to breakdown of the control mechanisms in the intestinal tissue that normally remove water from the stools, and in severe cases, the entry of pathogenic organisms into the bloodstream. Anemia may also arise due to the blood loss through diarrhea.[citation needed]

Bacterial infections that cause bloody diarrhea are typically classified as being either invasive or toxogenic. Invasive species cause damage directly by invading into the mucosa. The toxogenic species do not invade, but cause cellular damage by secreting toxins, resulting in bloody diarrhea. This is also in contrast to toxins that cause watery diarrhea, which usually do not cause cellular damage, but rather they take over cellular machinery for a portion of life of the cell.[18]

Definitions of dysentery can vary by region and by medical specialty. The U. S. Centers for Disease Control and Prevention (CDC) limits its definition to "diarrhea with visible blood".[19] Others define the term more broadly.[20] These differences in definition must be taken into account when defining mechanisms. For example, using the CDC definition requires that intestinal tissue be so severely damaged that blood vessels have ruptured, allowing visible quantities of blood to be lost with defecation. Other definitions require less specific damage.[citation needed]

Amoebic dysentery

[edit]
Main article: Amoebiasis

Amoebiasis, also known as amoebic dysentery, is caused by an infection from the amoeba Entamoeba histolytica,[21] which is found mainly in tropical areas.[22] Proper treatment of the underlying infection of amoebic dysentery is important; insufficiently treated amoebiasis can lie dormant for years and subsequently lead to severe, potentially fatal, complications.[citation needed]

When amoebae inside the bowel of an infected person are ready to leave the body, they group together and form a shell that surrounds and protects them. This group of amoebae is known as a cyst, which is then passed out of the person's body in the feces and can survive outside the body. If hygiene standards are poor – for example, if the person does not dispose of the feces hygienically – then it can contaminate the surroundings, such as nearby food and water. If another person then eats or drinks food or water that has been contaminated with feces containing the cyst, that person will also become infected with the amoebae. Amoebic dysentery is particularly common in parts of the world where human feces are used as fertilizer. After entering the person's body through the mouth, the cyst travels down into the stomach. The amoebae inside the cyst are protected from the stomach's digestive acid. From the stomach, the cyst travels to the intestines, where it breaks open and releases the amoebae, causing the infection. The amoebae can burrow into the walls of the intestines and cause small abscesses and ulcers to form. The cycle then begins again.[citation needed]

Bacillary dysentery

[edit]
Main article: Bacillary dysentery

Dysentery may also be caused by shigellosis, an infection by bacteria of the genus Shigella, and is then known as bacillary dysentery (or Marlow syndrome). The term bacillary dysentery etymologically might seem to refer to any dysentery caused by any bacilliform bacteria, but its meaning is restricted by convention to Shigella dysentery.[citation needed]

Other bacteria

[edit]

Some strains of Escherichia coli cause bloody diarrhea. The typical culprits are enterohemorrhagic Escherichia coli, of which O157:H7 is the best known. These types of E. coli also make Shiga toxin.[23]

Diagnosis

[edit]

A diagnosis may be made by taking a history and doing a brief examination. Dysentery should not be confused with hematochezia, which is the passage of fresh blood through the anus, usually in or with stools.[24]

Physical exam

[edit]

The mouth, skin, and lips may appear dry due to dehydration. Lower abdominal tenderness may also be present.[17]

Stool and blood tests

[edit]

Cultures of stool samples are examined to identify the organism causing dysentery. Usually, several samples must be obtained due to the number of amoebae, which changes daily.[17] Blood tests can be used to measure abnormalities in the levels of essential minerals and salts.[17]

Prevention

[edit]

Efforts to prevent dysentery include hand washing and food safety measures while traveling in areas of high risk.[4]

Vaccine

[edit]

Although there is currently no vaccine that protects against Shigella infection, several are in development.[25][26] Vaccination may eventually become a part of the strategy to reduce the incidence and severity of diarrhea, particularly among children in low-resource settings. For example, Shigella is a longstanding World Health Organization (WHO) target for vaccine development, and sharp declines in age-specific diarrhea/dysentery attack rates for this pathogen indicate that natural immunity does develop following exposure; thus, vaccination to prevent this disease should be feasible. The development of vaccines against these types of infection has been hampered by technical constraints, insufficient support for coordination, and a lack of market forces for research and development. Most vaccine development efforts are taking place in the public sector or as research programs within biotechnology companies.[citation needed]

Treatment

[edit]

Dysentery is managed by maintaining fluids using oral rehydration therapy.[4] If this treatment cannot be adequately maintained due to vomiting or the profuseness of diarrhea, hospital admission may be required for intravenous fluid replacement. In ideal situations, no antimicrobial therapy should be administered until microbiological microscopy and culture studies have established the specific infection involved. When laboratory services are not available, it may be necessary to administer a combination of drugs, including an amoebicidal drug to kill the parasite, and an antibiotic to treat any associated bacterial infection.[citation needed] Laudanum (Deodorized Tincture of Opium) may be used for severe pain and to combat severe diarrhea.[citation needed]

If shigellosis is suspected and it is not too severe, letting it run its course may be reasonable – usually less than a week. If the case is severe, antibiotics such as ciprofloxacin or TMP-SMX may be useful. However, many strains of Shigella are becoming resistant to common antibiotics, and effective medications are often in short supply in developing countries. If necessary, a doctor may have to reserve antibiotics for those at highest risk for death, including young children, people over 50, and anyone suffering from dehydration or malnutrition.[citation needed]

Amoebic dysentery is often treated with two antimicrobial drugs such as metronidazole and paromomycin or iodoquinol.[27]

Prognosis

[edit]

With correct treatment, most cases of amoebic and bacterial dysentery subside within 10 days, and most individuals achieve a full recovery within two to four weeks after beginning proper treatment. If the disease is left untreated, the prognosis varies with the immune status of the individual patient and the severity of disease. Extreme dehydration can delay recovery and significantly raises the risk for serious complications including death.[28]

Epidemiology

[edit]

Insufficient data exists, but Shigella is estimated to have caused the death of 34,000 children under the age of five in 2013, and 40,000 deaths in people over five years of age.[25] Amoebiasis infects over 50 million people each year, of whom 50,000 die (one per thousand).[29]

History

[edit]

Shigella evolved with the human expansion out of Africa 50,000 to 200,000 years ago.[30]

The seed, leaves, and bark of the kapok tree have been used in traditional medicines by indigenous peoples of the rainforest regions in the Americas, west-central Africa, and Southeast Asia in the treatment of this disease.[31][32][33]

In 1915, Australian bacteriologist Fannie Eleanor Williams was serving as a medic in Greece with the Australian Imperial Force, receiving casualties directly from Gallipoli. In Gallipoli, dysentery was severely affecting soldiers and causing significant loss of manpower. Williams carried out serological investigations into dysentery, co-authoring several groundbreaking papers with Sir Charles Martin, director of the Lister Institute.[34] The result of their work into dysentery was increased demand for specific diagnostics and curative sera.[35]

Bacillus subtilis was marketed throughout America and Europe from 1946 as an immunostimulatory aid in the treatment of gut and urinary tract diseases such as rotavirus and Shigella,[36] but declined in popularity after the introduction of consumer antibiotics.

Notable cases

[edit]
A Red Army soldier dies of dysentery after eating unwashed vegetables. This is a common way of contracting dysentery. From a health advisory pamphlet given to soldiers.

See also

[edit]

References

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Dysentery

View on Grokipedia
from Grokipedia
Dysentery is an of the intestines that causes severe containing visible and mucus, often resulting in , fever, and . It is classified into two main types: bacillary dysentery, caused by bacteria such as species, and amoebic dysentery, caused by the protozoan parasite . This condition primarily affects populations in areas with poor and is a significant contributor to global diarrhoeal diseases, which cause millions of cases annually, particularly among children under five years old. The primary symptoms of dysentery include frequent loose or watery stools with blood, mucus, or both, along with cramping , tenesmus (a sensation of incomplete evacuation), , , and sometimes high fever. In severe cases, especially with Shigella dysenteriae type 1, complications such as seizures, intestinal , or can occur, leading to high mortality if untreated. Symptoms typically appear 1–4 days after and last 5–7 days in uncomplicated cases, though can develop rapidly and pose life-threatening risks, particularly in young children, the elderly, and immunocompromised individuals. Dysentery spreads through the fecal-oral route, often via ingestion of contaminated or , direct contact with infected persons, or poor personal hygiene, requiring only a small inoculum of pathogens to cause . It is more prevalent in tropical and subtropical regions with inadequate and , and outbreaks can occur in settings like daycares, schools, or during travel to endemic areas. Treatment focuses on rapid rehydration using oral rehydration salts (ORS) or intravenous fluids for severe dehydration, alongside supportive care like rest and electrolyte replacement. For bacterial dysentery, antibiotics such as ciprofloxacin or azithromycin may be prescribed, though antimicrobial resistance is an emerging concern; amoebic dysentery requires specific antiparasitic drugs like metronidazole followed by a luminal agent. Prevention relies on access to safe drinking water, proper sanitation, thorough handwashing with soap, safe food handling practices, and vaccination where available.

Definition and Classification

Definition

Dysentery is an inflammatory disorder of the intestine, particularly the colon, that results in frequent passage of watery stools containing and . This arises from of the colonic mucosa, leading to a more severe presentation than non-inflammatory diarrheal conditions. The (WHO) defines dysentery as acute bloody , specifically any diarrheal episode in which loose or watery stools contain visible red , with itself characterized by three or more such stools per day. It is distinguished from simple by the hallmark presence of (passage of fresh in stool) and associated mucosal , rather than just increased stool liquidity without these features. Modern definitions from WHO and medical authorities emphasize its severe nature, often involving tenesmus—a painful urge to defecate—and potential systemic effects like . Severity of dysentery is gauged by factors such as stool frequency exceeding three episodes per day with blood, alongside levels classified by WHO as no dehydration (absence of key signs), some dehydration (e.g., two or more of restlessness, sunken eyes, or thirsty drinking), or severe dehydration (e.g., two or more of , very sunken eyes, or skin pinch recovery ≥2 seconds). These criteria highlight dysentery's potential for rapid fluid loss and life-threatening complications if untreated. Dysentery is typically infectious in origin.

Types

Dysentery is primarily classified as infectious, resulting from protozoal or bacterial pathogens invading the intestinal mucosa, or rarely as non-infectious due to conditions such as ischemia or chemical exposure that mimic the of bloody diarrhea. Infectious forms predominate globally, while non-infectious variants are uncommon and often linked to underlying vascular or toxic insults. Key subtypes of infectious dysentery include amoebic dysentery caused by , bacillary dysentery from species, balantidial dysentery due to , and schistosomal dysentery associated with or related species. Classification relies on the causative agent, with distinctions in clinical course—such as acute onset for bacillary versus potentially chronic progression for amoebic—and geographical prevalence, where protozoal types like amoebic and schistosomal are more endemic in tropical and subtropical regions with poor . Symptoms of bloody, mucoid with are common across types, though detailed manifestations vary.
TypeOnsetDurationEndemicity
Amoebic2–4 weeksAcute to chronic/, poor
Bacillary1–2 days5–7 daysWorldwide, higher in developing areas
BalantidialAcute or chronicProlonged if symptomaticWorldwide, pig-farming regions
Schistosomal1–3 monthsChronic, ,
Non-infectious (e.g., ischemic)Variable, often acuteVariableNot endemic; associated with

Clinical Features

Signs and Symptoms

Dysentery is characterized by the sudden onset of frequent, small-volume stools containing blood and , often accompanied by severe abdominal cramps and pain. Patients typically experience tenesmus, a painful sensation of incomplete defecation and urgent need to pass stool despite empty bowels. Fever is common, particularly in caused by species, where it may reach high levels during the acute phase. In amoebic dysentery due to , symptoms include abdominal cramps, with 3 to 8 semiformed stools per day containing and occasional blood, and less pronounced fever. The disease often progresses rapidly in its acute form, with bacillary dysentery presenting a sudden onset of high fever, frequent bloody, mucoid , and intense within 1 to 3 days of . Amoebic dysentery may follow a subacute or chronic course, lasting weeks to months, leading to gradual , recurrent episodes of bloody stools, and persistent . develops quickly due to fluid loss, manifesting as sunken eyes, dry mucous membranes, reduced output, extreme , and . Systemic effects include and , which exacerbate fluid loss and contribute to imbalances such as or , potentially progressing to in severe cases. In prolonged or untreated infections, complications like may occur, particularly in children with intense straining during . Dysentery tends to be more fulminant in young children and the elderly, with higher risks of rapid , , and mortality due to immature or compromised immune responses and reduced physiological reserves.

Pathophysiology

Dysentery arises from the invasion of the colonic mucosa by pathogens, primarily bacteria such as species or protozoa like , resulting in acute , mucosal ulceration, and formation of pseudomembranes composed of , inflammatory cells, and necrotic debris. This process disrupts the epithelial barrier, allowing bacterial translocation and exacerbating local tissue damage through the release of pro-inflammatory mediators. In bacterial dysentery, pathogens like initiate infection by attaching to and invading the colonic via M cells in Peyer's patches, followed by direct entry into enterocytes through actin cytoskeleton rearrangement and evasion of . S. dysenteriae type 1 produces , which inhibits protein synthesis and induces in macrophages and epithelial cells by triggering endoplasmic reticulum stress and activation, leading to cell death and release of interleukin-1 (IL-1) and IL-8. These cytokines amplify the inflammatory response, recruiting neutrophils that further degrade the mucosal barrier via and proteases, contributing to ulceration and bloody . Additionally, enterotoxins such as Shigella enterotoxin 1 and 2 promote fluid secretion, worsening . For protozoal dysentery, E. histolytica trophozoites adhere to colonic epithelial cells via the Gal/GalNAc lectin, employing contact-dependent through mechanisms including pore-forming amebapores and , where the parasite "bites" and ingests host cell membrane fragments, causing rapid target without . This direct tissue destruction triggers an inflammatory cascade, with epithelial cells releasing like IL-8 to attract neutrophils, whose influx perpetuates mucosal injury and ulcer formation. Unlike bacterial forms, protozoal invasion often involves less toxin-mediated but emphasizes mechanical and of host debris. The disease progresses in stages: initial pathogen attachment and mucosal penetration, followed by and local replication; an ensuing inflammatory cascade marked by influx and , which erodes the and produces bloody, mucoid stools; and, in severe cases, systemic dissemination leading to bacteremia or due to barrier breach. Pseudomembrane formation occurs as a result of fibrinous over denuded areas, potentially complicating healing. Host factors significantly influence susceptibility and severity, with impaired immunity—such as in , , or infancy—reducing effective and T-cell responses, thereby allowing unchecked proliferation and heightened inflammation. Gut barrier disruption from initial invasion impairs integrity, facilitating further microbial entry and amplifying fluid loss through enterotoxin-induced chloride secretion and osmotic diarrhea. In vulnerable individuals, these factors can escalate local to or extraintestinal spread.

Etiology

Protozoal Causes

Protozoal dysentery primarily results from infection by the protozoan parasite , which causes and leads to invasive intestinal disease characterized by bloody . The life cycle of E. histolytica begins with the of mature, quadrinucleated cysts through fecally contaminated food or water; these cysts excyst in the , releasing motile trophozoites that colonize the . The trophozoites adhere to colonic epithelial cells via a surface Gal/GalNAc lectin, facilitating contact-dependent through pore-forming peptides like amoebapores, while cysteine proteases degrade the and tight junctions, enabling tissue and the formation of characteristic flask-shaped ulcers in the intestinal mucosa. This invasive process disrupts the mucosal barrier, leading to ulceration, , and the clinical manifestation of dysentery. Globally, E. histolytica infection accounts for an estimated 40-50 million symptomatic cases annually, with higher prevalence in endemic regions such as India and sub-Saharan Africa, where poor sanitation and water quality exacerbate transmission. Prevalence varies widely; studies in India report ranges of 3-23% in asymptomatic populations, while pooled estimates for E. histolytica/E. dispar among school children in Africa are around 13%, though E. dispar is non-pathogenic and often indistinguishable without molecular testing. Approximately 90% of infections remain asymptomatic, resulting in chronic carriage where trophozoites or cysts persist in the gut without causing overt disease, serving as a reservoir for further transmission. Diagnostic hallmarks unique to protozoal etiology include histological evidence of flask-shaped ulcers with trophozoites containing ingested red blood cells, distinguishing it from other causes. A rarer protozoal cause is , a ciliated protozoan and the only known to infect humans, typically acquired zoonotically from pigs via the fecal-oral route in tropical and subtropical regions. B. coli trophozoites invade the colonic mucosa, causing ulceration and dysentery similar to , though infections are infrequent and often self-limiting except in immunocompromised individuals. Prevalence is low globally, with most cases reported in areas with close human-pig contact, such as parts of and .

Bacterial Causes

Bacterial dysentery, also known as , is primarily caused by species of the genus , a group of Gram-negative, non-motile, facultative anaerobic belonging to the family . The four main species are Shigella dysenteriae, S. flexneri, S. boydii, and S. sonnei, with S. dysenteriae type 1 being the most virulent due to its production of , which damages vascular and exacerbates systemic complications. Transmission occurs via the fecal-oral route, often through contaminated food or water, and requires a remarkably low infectious dose of just 10–100 organisms, enabling rapid spread in areas with poor . Shigella initiates infection by invading the colonic mucosa after ingestion, targeting M cells in Peyer's patches to cross the epithelial barrier. Once inside, the bacteria use a type III secretion system (T3SS), encoded on a 220-kb virulence plasmid, to inject effector proteins such as IpaB, IpaC, and IpaD into host cells, triggering actin cytoskeleton rearrangement and membrane ruffling for entry. Intracellularly, Shigella escapes the vacuole via IpaB and IpaC-mediated lysis, replicates in the cytoplasm, and spreads to adjacent cells through actin-based motility driven by IcsA (VirG), avoiding extracellular exposure and immune detection. In S. dysenteriae type 1, Shiga toxin—a potent AB5 toxin—further contributes to pathology by inhibiting protein synthesis in endothelial cells, leading to bloody diarrhea and potential hemolytic uremic syndrome. This invasive strategy induces intense inflammation, apoptosis in infected cells, and neutrophil influx, hallmarks of the disease's rapid onset. Other bacteria can also cause dysentery-like illness with bloody, mucoid stools, though less classically than . , a curved, motile Gram-negative rod, is a common enteric that invades , producing cytolethal distending and triggering Guillain-Barré in about 1 in 1,000 cases due to molecular mimicry with gangliosides. Non-typhoidal species, such as S. enterica serovars Typhimurium and Enteritidis, cause invasive resembling dysentery through T3SS-mediated invasion and production, while typhoidal strains like S. Typhi lead to enteric fever with occasional . species, opportunistic Gram-negative rods, are implicated in severe, bloody particularly in immunocompromised individuals, where they produce aerolysin and hemolysins that disrupt epithelial integrity.

Other Causes

Helminthic infections, particularly , can cause dysentery-like syndromes through egg deposition leading to granulomatous . This parasite is endemic in parts of , the , and , where eggs deposited in the intestinal venules provoke an inflammatory response, resulting in polypoid masses, ulceration, and bloody diarrhea mimicking . Viral causes of dysentery-like symptoms are rare but significant in immunocompromised individuals, such as those with . (CMV) infection can lead to hemorrhagic , characterized by , fever, and bloody due to mucosal ulceration and in the colon. Clostridium difficile, an emerging pathogen often following use, produces pseudomembranous that presents with profuse watery or bloody , abdominal cramps, and fever. The infection arises from toxin-mediated damage to the colonic mucosa, forming adherent pseudomembranes of , , and inflammatory cells, distinguishing it from invasive bacterial dysenteries. Although dysentery is an infectious disease, non-infectious conditions can present with similar symptoms of bloody . , prevalent in the elderly due to vascular occlusion or hypoperfusion, causes sudden and bloody from mucosal ischemia and sloughing. Chemical irritants, such as chronic laxative abuse, can induce colitis-like inflammation and chronic , sometimes progressing to ischemic changes. Radiation-induced colitis, occurring after pelvic radiotherapy, results in mucosal damage leading to , tenesmus, and rectal bleeding, with chronic forms showing telangiectasias and friability. These alternative infectious and non-infectious etiologies typically lack direct microbial invasion of the colonic characteristic of classic dysentery, instead producing symptoms through mechanisms such as production, vascular compromise, or inflammatory cascades triggered by irritants.

Diagnosis

Clinical Assessment

The clinical assessment of suspected dysentery begins with a thorough history to identify risk factors and severity indicators. Key elements include inquiring about recent travel to endemic areas, such as regions in , , or , where protozoal and bacterial causes are prevalent. Recent use should be noted, as it may predispose to certain infections or alter susceptibility, while exposure to contacts with diarrheal illness points to potential outbreaks. assessment involves evaluating fluid intake and output, with attention to (WHO) danger signs such as lethargy, inability to drink, or sunken eyes, which signal severe cases requiring urgent intervention. Physical examination focuses on signs of and abdominal involvement to gauge acuity. Vital signs may reveal or hypotension indicative of from fluid loss. is graded by skin turgor (reduced elasticity), prolonged time greater than 2 seconds, and dry mucous membranes. Abdominal palpation often elicits tenderness, particularly in the right for amoebic dysentery, though diffuse lower quadrant is common in bacterial forms; increased bowel sounds may accompany crampy discomfort. Risk stratification identifies high-risk groups, including children under 5 years, elderly individuals, and those who are , as they face elevated morbidity from and complications. In these populations, examination should include nutritional status evaluation, such as checking for or low weight-for-age, alongside signs, to prioritize aggressive management. Malnutrition exacerbates severity, increasing the likelihood of prolonged illness and systemic effects. Differential clues from history and exam help distinguish dysentery from mimics; an acute onset with bloody stools and fever contrasts with the chronic, relapsing course of . Localized right lower quadrant pain with rebound tenderness suggests rather than the more diffuse abdominal involvement typical of dysentery.

Laboratory Investigations

Laboratory investigations for dysentery aim to confirm the infectious and guide , typically initiated following clinical suspicion of bloody diarrhea. Stool specimens are the cornerstone of , with fresh samples preferred to preserve viability and morphology. Stool microscopy involves direct wet-mount examination of fresh, unpreserved stool for motile trophozoites of in amoebic dysentery, where the presence of ingested red blood cells (hematophagous activity) serves as a feature with a sensitivity of approximately 60%. For bacterial causes like , microscopy detects fecal leukocytes (≥3 per in multiple fields), indicating inflammatory with a sensitivity of 60-70%, though this is nonspecific and supports the need for further testing. Permanent stains such as trichrome may enhance cyst detection but require expertise to differentiate pathogenic E. histolytica from nonpathogenic E. dispar. Stool culture remains the gold standard for bacterial dysentery, using selective media such as (where Shigella appears as colorless, lactose-nonfermenting colonies) or for isolation and identification, confirmed by biochemical tests and serotyping. Sensitivity varies widely (typically 40-80% in studies) and is influenced by sample timing, conditions, and prior use, which can significantly reduce yield. For amoebic cases, culture is less common due to fastidious growth requirements. Antigen detection assays, such as enzyme immunoassays (EIA) targeting E. histolytica Gal/GalNAc in stool, offer rapid results with sensitivity of 86-98% and specificity of 93-100%, outperforming microscopy and distinguishing pathogenic from nonpathogenic species. For Shigella, rapid immunochromatographic tests like latex or methods detect specific with approximately 85% sensitivity, enabling bedside in resource-limited settings. Molecular methods, including (PCR), provide high-throughput detection of multiple pathogens. Multiplex real-time PCR panels targeting Shigella invasion plasmid antigen H (ipaH) gene or E. histolytica 18S rRNA demonstrate sensitivities exceeding 95% and specificities near 100% for key dysentery agents, with advantages in low-burden infections and antibiotic-exposed patients. These assays are increasingly available in clinical labs but may require specialized equipment. Blood tests complement stool analysis; complete blood count (CBC) often reveals leukocytosis (white blood cell count >11,000/μL) in shigellosis, reflecting systemic inflammation. Serology for amoebic dysentery detects anti-lectin IgG antibodies via ELISA, with sensitivity >90% and specificity >85% in chronic or invasive cases, though it cannot distinguish active from past infection. Electrolyte panels assess for hyponatremia or hypokalemia due to fluid losses, guiding supportive care. In non-resolving or complicated cases, advanced procedures like with may visualize characteristic flask-shaped ulcers in amoebic or pseudomembranes in , confirmed histologically, though these are reserved for atypical presentations due to invasiveness.

Prevention

Hygiene and Sanitation

Personal hygiene practices play a crucial role in preventing dysentery transmission through the fecal-oral route. Handwashing with after and before food preparation can reduce the risk of diarrheal diseases, including dysentery, by 30-47%, as demonstrated in multiple community-based trials. Safe handling further mitigates risks; boiling water effectively kills pathogens like , which causes , while avoiding raw or undercooked produce in endemic areas prevents contamination from fecal sources. Sanitation infrastructure improvements are essential for breaking dysentery transmission chains at the community level. Access to clean water, with WHO recommending a minimum of 20 liters per person per day for drinking, cooking, and basic , significantly lowers exposure to contaminated sources. In urban slums, constructing latrines reduces , which contributes to fecal contamination of water and soil, thereby decreasing dysentery incidence by limiting environmental spread of pathogens like . Community-level interventions enhance these efforts through targeted education and . UNICEF-led campaigns in promote behaviors, such as proper handwashing and safe disposal of children's , to combat diarrheal diseases including dysentery in high-burden regions. Effective practices, including proper and solid waste handling, reduce fecal contamination in household environments, preventing proliferation that leads to dysentery outbreaks. Evidence from rigorous trials underscores the impact of integrated , , and (WASH) interventions. In , the WASH Benefits cluster-randomized trial showed that combined WASH measures reduced child prevalence by 30-40%, with similar effects expected for dysentery due to shared transmission pathways. 30031-2/fulltext) These reductions highlight how scalable WASH strategies can avert significant in endemic settings.

Vaccination and Prophylaxis

As of 2025, no licensed vaccine exists globally for preventing shigellosis, the bacterial form of dysentery caused by Shigella species, despite ongoing development of several candidates. Experimental live-attenuated oral vaccines, such as CVD 1208S targeting Shigella flexneri 2a, have shown promising results in phase II challenge trials, with approximately 70% protective efficacy against S. flexneri infection in healthy adults. This candidate remains in early clinical stages, with combined Shigella-enterotoxigenic E. coli formulations like CVD 1208S-122 advancing to phase I trials for safety and immunogenicity assessment. The World Health Organization (WHO) prioritizes Shigella vaccine development for children in endemic low- and middle-income countries, emphasizing the need for affordable options to address antimicrobial resistance and high disease burden. For amoebic dysentery caused by , no vaccine is available, and preventive efforts rely on non-immunological measures. Research focuses on recombinant antigens from the Gal/GalNAc , a key parasite adhesion protein, which has demonstrated immunogenicity and partial protection in preclinical animal models of intestinal amebiasis and . For instance, subunit vaccines incorporating the LecA fragment of Gal-, adjuvanted with GLA-SE or liposomal formulations, elicited responses in rhesus macaques without advancing to human trials as of 2025. These efforts highlight the lectin's role as a leading target, though challenges in achieving sterilizing immunity persist. Chemoprophylaxis plays a limited role in dysentery prevention, primarily for high-risk travelers to endemic areas. Short-term antibiotic prophylaxis with (500 mg daily) has demonstrated up to 95% efficacy in preventing traveler's , including , but is recommended only for short durations (e.g., 1-3 weeks) to minimize risks. In children under 5 years in resource-limited settings, supplementation (10-20 mg daily for 10-14 days) during acute diarrheal episodes, including dysentery, reduces symptom duration by about 25% and lowers the incidence of persistent . The WHO endorses for routine use in managing childhood in endemic regions, particularly , where trials for vaccine rollout are underway to complement such interventions.

Treatment

Supportive Care

Supportive care for dysentery primarily focuses on correcting and maintaining nutritional status, as these measures address the most immediate threats to life regardless of the underlying . The cornerstone of management is rehydration, which prevents and reduces mortality. Oral rehydration solution (ORS) is recommended for patients with no or some , using the World Health Organization's low-osmolarity formula containing 75 mmol/L sodium and 75 mmol/L glucose, administered as 50-100 mL per kg body weight over 4 hours for children under 2 years or 100-200 mL after each loose stool for older children. For severe , defined as more than 10% fluid loss with signs like or sunken eyes, intravenous fluids such as Ringer's lactate are initiated at 100 mL/kg, with 30 mL/kg given in the first hour for infants or 30 minutes for older children, followed by the remainder over 5 or 2.5 hours, respectively. Nutritional support emphasizes continued feeding to avoid , which exacerbates dysentery outcomes. should be maintained or resumed promptly in infants, while older children receive frequent small meals with easily digestible foods. In cases of suspected transient , common in bacterial dysentery due to mucosal damage, lactose-free diets using alternatives like soy-based formulas are advised temporarily to reduce osmotic . supplementation is routinely recommended for children under 5 years, at 20 mg per day for 10-14 days (or 10 mg for those under 6 months), as it shortens episode duration by about 25% and reduces severity. Close monitoring is essential to guide and prevent complications. Daily measurements track rehydration progress, aiming for a 5-10% gain in the first 24 hours, while output should be assessed to ensure at least 0.5-1 mL/kg/hour, indicating adequate renal perfusion. , including and blood pressure, are checked frequently during initial treatment. According to 2024 World Health Organization guidelines, rapid initiation of ORS has significantly reduced diarrhea-related mortality in settings with effective supportive care.

Antimicrobial Therapy

Antimicrobial therapy for dysentery is tailored to the underlying pathogen, with bacterial (bacillary) dysentery primarily caused by Shigella species treated using antibiotics, while amoebic dysentery caused by Entamoeba histolytica requires antiparasitic agents. Selection of agents depends on local resistance patterns, patient factors, and susceptibility testing, as resistance has significantly impacted treatment efficacy. While supportive rehydration remains foundational, antimicrobials shorten the duration of symptoms and reduce transmission risk when appropriately used. For , first-line oral antibiotics in adults include at 500 mg twice daily for 3 days or at 500 mg once daily for 3 days, effective against susceptible strains by inhibiting bacterial replication and expediting recovery. In cases of multidrug-resistant (MDR) , particularly strains resistant to multiple first-line agents, intravenous (1-2 g daily) serves as an alternative, often guided by stool culture and sensitivity results to ensure . Extensively drug-resistant (XDR) strains, resistant to , , and , have emerged as of 2025, particularly affecting high-risk groups such as men who have sex with men and people with , necessitating susceptibility testing and potential use of alternatives like fosfomycin or . Antimicrobial stewardship is critical due to the global rise in quinolone-resistant , with resistance rates reaching up to 95% in regions of as reported in 2024 surveillance data, necessitating routine susceptibility testing and avoidance of empiric quinolone use in high-prevalence areas. Anti-motility agents, such as , must be avoided, as they can prolong toxin retention in the gut and exacerbate complications like . Amoebic dysentery treatment involves a two-phase approach: tissue-active agents to eliminate invasive trophozoites followed by luminal agents to eradicate cysts and prevent relapse. Metronidazole, at 750 mg orally three times daily for 10 days, is the standard tissue amebicide, acting by disrupting parasite DNA and effectively resolving invasive disease in most cases. This is followed by a luminal agent such as paromomycin (25-35 mg/kg/day orally, divided into three doses for 7 days), which targets intestinal cysts without significant systemic absorption, or iodoquinol (650 mg orally three times daily for 20 days) as an alternative for cyst clearance. Resistance to metronidazole remains rare, but combination therapy ensures comprehensive eradication, with paromomycin preferred in scenarios requiring minimal systemic exposure. Special considerations apply in to balance maternal treatment with safety. For bacterial dysentery, erythromycin (500 mg orally four times daily for 5 days) is a suitable alternative to quinolones due to its established safety profile and efficacy against in this population. For amoebic dysentery, is the preferred luminal agent throughout , as it is not absorbed and poses no known risk to the , while is generally deferred until the second or third trimester if needed for invasive disease. In all cases, therapy should be initiated promptly under medical supervision to mitigate risks of prolonged illness.

Prognosis and Complications

Prognosis

With prompt access to treatment, the mortality rate for dysentery is typically less than 1%, as effective antimicrobial therapy and supportive measures like oral rehydration significantly reduce risks of severe outcomes. In untreated cases, particularly among children under five in resource-limited settings or during epidemics, mortality can reach up to 20%, driven by and secondary infections. Most uncomplicated cases resolve within 1-2 weeks with hydration and pathogen clearance. Prognosis varies by etiology: (shigellosis) is often self-limiting in immunocompetent individuals, with most recovering without antibiotics, whereas amoebic dysentery carries a greater risk of progression to extraintestinal involvement, including in approximately 10% of invasive cases. Long-term sequelae in amoebic dysentery include chronic carriage of in 5-10% of inadequately treated cases, which may lead to recurrent episodes if reinfection or persistence occurs. According to 2021 estimates from the , diarrheal diseases (encompassing dysentery) caused 1.17 million deaths globally, with a case-fatality rate of approximately 0.07%, reflecting declines due to scaled-up use of oral rehydration salts (ORS) and improved sanitation in high-burden areas. Dysentery-specific case-fatality rates can be higher, up to 4% in untreated epidemics. Complications such as can worsen prognosis but are detailed separately.

Complications

Dysentery can lead to several acute complications, particularly in severe bacterial cases caused by species. , characterized by nonobstructive colonic dilation greater than 6 cm accompanied by systemic toxicity, is a rare but life-threatening primarily associated with or S. dysenteriae type 1 infections. This condition arises from intense mucosal inflammation and toxin-mediated damage, carrying a high risk of colonic perforation, which can result in and if not promptly managed. Another acute complication is hemolytic-uremic syndrome (HUS), triggered by Shiga toxin-producing strains such as S. dysenteriae type 1, occurring in approximately 10-13% of affected children. HUS manifests as , , and , often developing 1-5 days after dysentery onset. Chronic complications may emerge following resolution of the acute infection. Post-infectious irritable bowel syndrome (IBS) develops in about 13-20% of individuals after bacillary dysentery, such as that caused by Shigella, persisting for months to years due to lingering gut dysmotility and low-grade inflammation. In amoebic dysentery from Entamoeba histolytica, invasive disease progresses to amoebic liver abscess in 1-3% of cases, forming pus-filled cavities in the liver via hematogenous spread of trophozoites. These abscesses are typically diagnosed via ultrasound, which reveals hypoechoic lesions with well-defined walls, often in the right hepatic lobe. In vulnerable populations, such as children or those with underlying , dysentery exacerbates through prolonged and reduced nutrient absorption, leading to growth stunting and increased susceptibility to secondary infections. Neurological effects, including seizures, can arise from severe induced by fluid losses and electrolyte imbalances during acute . These seizures are often generalized tonic-clonic and may occur with severe (typically below 120 mEq/L), necessitating urgent correction to prevent . Early initiation of appropriate antibiotics significantly mitigates complication risks; for instance, prompt therapy in amoebic dysentery reduces the likelihood of formation by up to 80% by eradicating invasive trophozoites before extraintestinal dissemination. Such interventions also lower the incidence of HUS in by limiting production, though supportive care remains essential. The occurrence of these complications adversely influences overall by increasing mortality and long-term morbidity.

Epidemiology

Global Burden

Dysentery represents a major challenge worldwide, particularly in low- and middle-income countries, where poor and limited access to clean water exacerbate its spread. As of the Global Burden of Disease (GBD) Study 2021, (bacillary dysentery) is estimated to cause 125–165 million cases annually, while (amoebic dysentery) leads to around 50 million symptomatic cases, predominantly caused by species and , respectively. These cases are heavily concentrated in regions with inadequate , leading to severe bloody that can rapidly escalate to life-threatening and systemic complications. Shigella contributes to approximately 24% of diarrhoeal deaths in children under 5 years. Mortality from dysentery is significant but lower than broader diarrhoeal estimates, with around 200,000 deaths annually, including approximately 82,000 from in children under 5 and about 100,000 from , the vast majority affecting young children in low-income settings such as and . This disproportionate impact on young children underscores the disease's role as a leading cause of pediatric mortality in endemic areas, where and co-infections further amplify vulnerability. The burden is quantified through disability-adjusted life years (DALYs), with alone accounting for about 7.3 million DALYs in children under 5 in 2021, and combined dysentery forms estimated at 10–15 million DALYs globally, reflecting both premature deaths and long-term from recurrent episodes and sequelae like . Sub-Saharan Africa bears the highest DALY burden, followed closely by , where environmental and socioeconomic factors sustain high transmission rates. Epidemiological trends indicate substantial progress globally, with diarrhoeal deaths decreasing by 60% from 1990 to 2021 per GBD estimates, including declines in due to and interventions. However, this reduction is offset by the growing threat of , which has increased the severity of infections and reduced treatment , potentially reversing gains in affected populations. In low-income regions, the economic toll of diarrhoeal diseases, including dysentery, strains resources through healthcare costs and productivity losses, perpetuating cycles of .

Transmission and Risk Factors

Dysentery, encompassing both bacillary and amoebic forms, is primarily transmitted through the fecal-oral route. In caused by species, occurs via of or contaminated with fecal matter, or through direct person-to-person contact, particularly in overcrowded settings with inadequate hygiene such as childcare centers and schools. Amoebic dysentery, resulting from , follows a similar pathway, with transmission via contaminated , , or objects touched by infected feces, often in areas lacking proper . Transmission is exacerbated by overcrowding, which facilitates person-to-person spread, especially among young children in communal environments like daycares for Shigella infections. Zoonotic aspects are notable for certain bacterial causes; Campylobacter jejuni, which can produce dysentery-like bloody diarrhea, spreads from animals such as poultry, cattle, and pets to humans through contaminated food (e.g., undercooked meat) or direct animal contact. Seasonality plays a key role, with incidence of bacillary dysentery peaking in the mid-rainy season due to flooding and runoff contaminating water sources, leading to significantly higher rates—often 2–3 times elevated—compared to dry periods. Key risk factors for acquiring dysentery include , which correlates with poor and increases diarrheal odds through limited access to clean water and facilities; studies report relative risks around 3.8–4.5 for dysentery in households with inadequate water sources or . further heightens vulnerability by impairing immune function, making individuals more susceptible to and severe outcomes from pathogens like Shigella. Travel to tropical or subtropical endemic areas elevates risk due to exposure to contaminated sources in regions with suboptimal hygiene infrastructure. HIV substantially amplifies the likelihood of severe shigellosis, with rate ratios up to 20 times higher among immunocompromised individuals compared to the general population. Epidemiological modeling underscores dysentery's moderate contagiousness; the basic reproduction number (R0) for Shigella in household settings is typically around 1.5, indicating limited secondary spread under normal conditions, though it rises higher during outbreaks in dense populations.

History

Early Recognition

The term dysentery derives from the ancient Greek word dysentería, meaning "bad intestine" or "ill intestine," a term coined by the physician Hippocrates around 400 BCE to describe a severe form of diarrhea accompanied by blood and mucus in the stools, often referred to as the "bloody flux." Hippocrates' accounts in works such as On the Sacred Disease and Epidemics detailed the condition's symptoms, including abdominal pain, fever, and tenesmus, attributing it to imbalances in bodily humors like phlegm and bile overflowing into the intestinal veins, causing ulceration. This early recognition established dysentery as a distinct gastrointestinal disorder, separate from simpler diarrheas, and laid the foundation for its study in Western medicine. In ancient non-Greek contexts, evidence of dysentery recognition appears in medical texts like the , dating to approximately 1550 BCE, which documents remedies for bloody stools and abdominal fluxes suggestive of the disease, including mixtures of honey, oil, and herbal porridges to soothe inflammation and staunch bleeding. By the 2nd century CE, advanced the understanding in his treatise On the Causes and Signs of Acute and Chronic Diseases, where he differentiated types of dysentery based on stool characteristics—such as mucous versus bloody forms—and intestinal lesions, emphasizing clinical progression from mild flux to severe ulceration while noting associations with diet and environment. These descriptions highlighted dysentery's inflammatory nature, influencing Roman and medieval physicians who built upon them without significant etiological breakthroughs until the microscopic era. The 19th century marked a pivotal shift with the advent of , enabling the identification of microbial causes; in 1875, Russian physician Friedrich Lösch first observed and described in the stools of a patient with dysenteric symptoms, linking the amoeba to tissue invasion and ulceration in what became known as amoebic dysentery. This discovery differentiated amoebic from bacillary forms, previously lumped together clinically. In the 20th century, the formalized dysentery's classification in the 1970s as acute bloody or inflammatory diarrhea, emphasizing its distinction from non-inflammatory types based on fecal blood, mucus, and systemic signs like fever. By 2025, updates to diagnostic guidelines integrate molecular techniques, such as multiplex PCR panels, for rapid pathogen detection—including Shigella species and —enhancing accuracy in resource-limited settings and refining classifications beyond microscopy alone.

Major Outbreaks and Notable Cases

Dysentery has been documented since ancient times, with archaeological evidence indicating its presence in during the 7th–6th centuries BCE. Analysis of sediments from two latrines—one from the Armon ha-Natziv ridge (mid-7th century BCE) and another from the House of Ahiel (8th–6th centuries BCE)—revealed the oldest known traces of , a protozoan parasite causing , a diarrheal disease characterized by severe watery , abdominal cramps, and . This endemic infection likely affected Jerusalem's population of 8,000–25,000 residents, exacerbated by poor , overcrowding, and contamination of and sources, leading to chronic effects such as and in children. In medieval Europe, dysentery frequently ravaged armies during the , contributing to high mortality rates amid unsanitary conditions. During the (1248–1254 CE), led by King , outbreaks of diarrhea plagued the French forces in , with the king himself suffering such frequent bouts that alterations were made to his clothing for convenience. Archaeological evidence from 13th-century latrines in Acre, a key Crusader stronghold, confirms the presence of dysentery-causing parasites; enzyme-linked immunosorbent assay () testing detected Entamoeba histolytica in six of eight samples from a latrine associated with the Order of St. John, and Giardia duodenalis in one sample, marking the first such identification in the using this method. Similarly, during the in 1415, King Henry V's endured a dysentery outbreak that weakened troops before their victory, highlighting the disease's role in . Dysentery emerged as a major scourge in modern military conflicts, often decimating forces due to contaminated water and poor hygiene. During Napoleon's 1812 retreat from , bacillary dysentery contributed significantly to the French army's losses, alongside other infections, in the harsh conditions. In the (1861–1865), dysentery accounted for approximately 285,000 cases among Federal troops alone, driven by bacterial pathogens in army camps and representing a leading cause of non-combat deaths. saw widespread in the British Expeditionary Force in , where was the predominant cause of dysentery, infecting thousands and straining medical resources amid . During that war, Australian Imperial Forces also experienced epidemics at Gallipoli in 1915 and in in 1918, with species causing outbreaks in challenging environments. brought further epidemics among Australian forces in Pacific theaters, where species caused recurrent outbreaks in tropical environments. The (1950–1953) further amplified incidence, with prevalent among troops due to disrupted sanitation. Postwar 20th-century epidemics underscored dysentery's persistence in civilian populations, particularly in regions with social upheaval. The 1897 outbreak in , caused by Shigella dysenteriae serotype 1, resulted in over 22,000 deaths with a 25% , prompting Kiyoshi Shiga's identification of the using novel techniques. A major epidemic swept from 1969 to 1973, starting in with S. dysenteriae type 1, affecting an estimated 500,000 people and causing 20,000 deaths; the strain's multidrug resistance complicated control efforts. In during the late to , similar multidrug-resistant S. dysenteriae type 1 strains fueled outbreaks in refugee camps in , , , and , with incidence rates reaching 3.8 cases per 100 persons weekly in Rwandan camps amid the 1994 genocide. These events, often linked to Shigella spread from European strains via and migration between 1889 and 1903, highlight dysentery's global impact in vulnerable settings. In the , dysentery continues to cause significant outbreaks, driven by antimicrobial-resistant strains. For instance, extensively drug-resistant Shigella sonnei infections emerged in in 2022, linked to travel from endemic areas. In the United States, a multidrug-resistant serotype 2a outbreak affected , from 2021 to 2023, involving over 200 cases among humans and animals. Ongoing epidemics in low- and middle-income countries, particularly among children under five, underscore the persistent burden, with causing an estimated 164,000 deaths annually as of 2025.

References

  1. https://www.emro.who.int/health-topics/dysentery/
  2. https://www.who.int/news-room/fact-sheets/detail/diarrhoeal-disease
  3. https://www.cdc.gov/amebiasis/about/index.html
  4. https://www.cdc.gov/shigella/hcp/clinical-overview/index.html
  5. https://www.cdc.gov/shigella/about/index.html
  6. https://www.cdc.gov/shigella/signs-symptoms/index.html
  7. https://www.sciencedirect.com/topics/medicine-and-dentistry/dysentery
  8. https://www.ncbi.nlm.nih.gov/books/NBK482337/
  9. https://www.ncbi.nlm.nih.gov/books/NBK554527/
  10. https://www.cdc.gov/dpdx/balantidiasis/index.html
  11. https://www.merckmanuals.com/professional/infectious-diseases/trematodes-flukes/schistosomiasis
  12. https://www.who.int/news-room/fact-sheets/detail/schistosomiasis
  13. https://pmc.ncbi.nlm.nih.gov/articles/PMC10380210/
  14. https://www.niddk.nih.gov/health-information/digestive-diseases/diarrhea/symptoms-causes
  15. https://pmc.ncbi.nlm.nih.gov/articles/PMC5423276/
  16. https://pubmed.ncbi.nlm.nih.gov/20204227/
  17. https://pmc.ncbi.nlm.nih.gov/articles/PMC8542808/
  18. https://pmc.ncbi.nlm.nih.gov/articles/PMC2855686/
  19. https://pubmed.ncbi.nlm.nih.gov/18005243/
  20. https://pmc.ncbi.nlm.nih.gov/articles/PMC7205191/
  21. https://pmc.ncbi.nlm.nih.gov/articles/PMC4567409/
  22. https://pmc.ncbi.nlm.nih.gov/articles/PMC2943803/
  23. https://www.ncbi.nlm.nih.gov/books/NBK557718/
  24. https://pmc.ncbi.nlm.nih.gov/articles/PMC100155/
  25. https://www.ncbi.nlm.nih.gov/books/NBK7742/
  26. https://pubmed.ncbi.nlm.nih.gov/35404011/
  27. https://pmc.ncbi.nlm.nih.gov/articles/PMC8870593/
  28. https://pmc.ncbi.nlm.nih.gov/articles/PMC6055529/
  29. https://pmc.ncbi.nlm.nih.gov/articles/PMC4724904/
  30. https://wwwnc.cdc.gov/eid/article/26/1/18-1698_article
  31. https://pmc.ncbi.nlm.nih.gov/articles/PMC5803893/
  32. https://pmc.ncbi.nlm.nih.gov/articles/PMC2223840/
  33. https://pmc.ncbi.nlm.nih.gov/articles/PMC4126259/
  34. https://www.cdc.gov/campylobacter/signs-symptoms/guillain-barre-syndrome.html
  35. https://pmc.ncbi.nlm.nih.gov/articles/PMC88896/
  36. https://www.ncbi.nlm.nih.gov/books/NBK555892/
  37. https://www.ncbi.nlm.nih.gov/books/NBK8435/
  38. https://pmc.ncbi.nlm.nih.gov/articles/PMC3373137/
  39. https://pmc.ncbi.nlm.nih.gov/articles/PMC10433960/
  40. https://pmc.ncbi.nlm.nih.gov/articles/PMC5598446/
  41. https://pmc.ncbi.nlm.nih.gov/articles/PMC5161784/
  42. https://pmc.ncbi.nlm.nih.gov/articles/PMC11992835/
  43. https://pmc.ncbi.nlm.nih.gov/articles/PMC4554353/
  44. https://www.ncbi.nlm.nih.gov/books/NBK431054/
  45. https://pmc.ncbi.nlm.nih.gov/articles/PMC4402243/
  46. https://pmc.ncbi.nlm.nih.gov/articles/PMC3577613/
  47. https://pmc.ncbi.nlm.nih.gov/articles/PMC10122613/
  48. https://pmc.ncbi.nlm.nih.gov/articles/PMC2780150/
  49. https://academic.oup.com/cid/article/65/12/e45/4557073
  50. https://www.ncbi.nlm.nih.gov/books/NBK154434/
  51. https://www.aafp.org/pubs/afp/issues/2009/1001/p692.html
  52. https://emedicine.medscape.com/article/212029-clinical
  53. https://emedicine.medscape.com/article/182767-clinical
  54. https://emedicine.medscape.com/article/773895-differential
  55. https://pmc.ncbi.nlm.nih.gov/articles/PMC7135126/
  56. https://pmc.ncbi.nlm.nih.gov/articles/PMC9876763/
  57. https://pmc.ncbi.nlm.nih.gov/articles/PMC207118/
  58. https://wwwnc.cdc.gov/eid/article/16/11/09-0934_article
  59. https://pmc.ncbi.nlm.nih.gov/articles/PMC10962731/
  60. https://pmc.ncbi.nlm.nih.gov/articles/PMC12541719/
  61. https://pubmed.ncbi.nlm.nih.gov/12726975/
  62. https://www.cdc.gov/clean-hands/data-research/facts-stats/index.html
  63. https://www.fda.gov/food/buy-store-serve-safe-food/safe-food-handling
  64. https://wwwnc.cdc.gov/travel/page/food-water-safety
  65. https://www.who.int/news-room/fact-sheets/detail/drinking-water
  66. https://www.who.int/news-room/fact-sheets/detail/sanitation
  67. https://pmc.ncbi.nlm.nih.gov/articles/PMC5414716/
  68. https://www.unicef.org/esa/sanitation-and-hygiene
  69. https://www.sciencedirect.com/science/article/pii/S0043135423012459
  70. https://pmc.ncbi.nlm.nih.gov/articles/PMC9978565/
  71. https://pmc.ncbi.nlm.nih.gov/articles/PMC5809718/
  72. https://www.mdpi.com/1422-0067/25/8/4329
  73. https://ctv.veeva.com/study/shigella-cvd-31000-study-of-responses-with-shigella-etec-vaccine-strain-cvd-1208s122
  74. https://www.who.int/publications/i/item/9789240036741
  75. https://pmc.ncbi.nlm.nih.gov/articles/PMC5396225/
  76. https://www.tandfonline.com/doi/full/10.1080/21645515.2024.2374147
  77. https://www.researchgate.net/publication/260120601_The_future_for_vaccine_development_against_Entamoeba_histolytica
  78. https://pmc.ncbi.nlm.nih.gov/articles/PMC1539099/
  79. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0010386
  80. https://www.who.int/teams/immunization-vaccines-and-biologicals/diseases/shigella
  81. https://cdn.who.int/media/docs/default-source/2021-dha-docs/pnadk428.pdf
  82. https://www.ncbi.nlm.nih.gov/books/NBK436022/
  83. https://www.who.int/tools/elena/interventions/zinc-diarrhoea
  84. https://www.cdc.gov/han/2023/han00486.html
  85. https://emedicine.medscape.com/article/182767-treatment
  86. https://www.cdc.gov/shigella/outbreaks/xdr-shigella-01-24/index.html
  87. https://www.mdpi.com/2079-6382/14/11/1091
  88. https://bestpractice.bmj.com/topics/en-us/553
  89. https://www.merckmanuals.com/professional/infectious-diseases/intestinal-protozoa-and-microsporidia/amebiasis
  90. https://www.drugs.com/pregnancy/erythromycin.html
  91. https://pmc.ncbi.nlm.nih.gov/articles/PMC5425222/
  92. https://emedicine.medscape.com/article/212029-overview
  93. https://academic.oup.com/cid/article-abstract/13/Supplement_4/S245/313872
  94. https://my.clevelandclinic.org/health/drugs/23567-dysentery
  95. https://fg.bmj.com/content/16/1/37
  96. https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00691-1/fulltext
  97. https://pubmed.ncbi.nlm.nih.gov/1421937/
  98. https://www.ncbi.nlm.nih.gov/books/NBK547679/
  99. https://pubmed.ncbi.nlm.nih.gov/22579556/
  100. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540501/1/Shigella_dysenteriae
  101. https://pmc.ncbi.nlm.nih.gov/articles/PMC4930305/
  102. https://www.revistagastroenterologiamexico.org/en-a-brief-history-amoebic-liver-articulo-S2255534X17300440
  103. https://www.ncbi.nlm.nih.gov/books/NBK430832/
  104. https://www.pasteur.fr/en/medical-center/disease-sheets/shigellosis
  105. https://www.mayoclinic.org/diseases-conditions/shigella/symptoms-causes/syc-20377529
  106. https://emedicine.medscape.com/article/907841-overview
  107. https://ghdx.healthdata.org/gbd-2021
  108. https://pmc.ncbi.nlm.nih.gov/articles/PMC12421937/
  109. https://www.who.int/publications/i/item/9789240116337
  110. https://pmc.ncbi.nlm.nih.gov/articles/PMC12273133/
  111. https://www.cdc.gov/shigella/prevention/preventing-shigella-infection-among-young-children.html
  112. https://www.cdc.gov/campylobacter/about/index.html
  113. https://pubmed.ncbi.nlm.nih.gov/28637484/
  114. https://pubmed.ncbi.nlm.nih.gov/19240352/
  115. https://www.cdc.gov/yellow-book/hcp/asia/india.html
  116. https://wwwnc.cdc.gov/eid/article/5/6/99-0614_article
  117. https://pubmed.ncbi.nlm.nih.gov/24008913/
  118. https://www.etymonline.com/word/dysentery
  119. https://pmc.ncbi.nlm.nih.gov/articles/PMC8559768/
  120. https://classics.mit.edu/Hippocrates/epidemics.1.i.html
  121. http://www.academia.dk/MedHist/Biblioteket/ebers-papyrus.php
  122. https://muse.jhu.edu/pub/1/article/4233
  123. https://www.cambridge.org/core/books/cambridge-world-history-of-human-disease/dysentery/6FCCF778D575C06EE939064C31D89C8C
  124. https://pubmed.ncbi.nlm.nih.gov/18483662/
  125. https://pmc.ncbi.nlm.nih.gov/articles/PMC10962728/
  126. https://pmc.ncbi.nlm.nih.gov/articles/PMC10410378/
  127. https://doi.org/10.1016/j.jas.2007.11.017
  128. https://jamanetwork.com/journals/jama/fullarticle/1157101
  129. https://jmvh.org/wp-content/uploads/2023/02/AMMA-JMVH-January-2023-G-D-Shanks.pdf
  130. https://pmc.ncbi.nlm.nih.gov/articles/PMC7113447/
  131. https://www.sanger.ac.uk/news_item/genomic-study-epidemic-dysentery-reveals-how-europe-exported-scourge-worldwide/
  132. https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON364
  133. https://www.nature.com/articles/s41467-025-59766-3
  134. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01033-5/fulltext
Add your contribution
Related Hubs
User Avatar
No comments yet.